BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38084674)

  • 21. Cuproptosis: Harnessing Transition Metal for Cancer Therapy.
    Wang W; Mo W; Hang Z; Huang Y; Yi H; Sun Z; Lei A
    ACS Nano; 2023 Oct; 17(20):19581-19599. PubMed ID: 37820312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy.
    Li Y; Liu J; Chen Y; Weichselbaum RR; Lin W
    Adv Sci (Weinh); 2024 Jun; 11(23):e2310309. PubMed ID: 38477411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stimulus-Responsive Copper Complex Nanoparticles Induce Cuproptosis for Augmented Cancer Immunotherapy.
    Hu F; Huang J; Bing T; Mou W; Li D; Zhang H; Chen Y; Jin Q; Yu Y; Yang Z
    Adv Sci (Weinh); 2024 Apr; 11(13):e2309388. PubMed ID: 38269649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting cuproplasia and cuproptosis in cancer.
    Tang D; Kroemer G; Kang R
    Nat Rev Clin Oncol; 2024 May; 21(5):370-388. PubMed ID: 38486054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of lipid metabolism on cuproptosis-inducing cancer therapy.
    Zhong Y; Zeng W; Chen Y; Zhu X
    Biomed Pharmacother; 2024 Mar; 172():116247. PubMed ID: 38330710
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Micronutrients/miRs/ATP networking in mitochondria: Clinical intervention with ferroptosis, cuproptosis, and calcium burden.
    Prasad Panda S; Kesharwani A
    Mitochondrion; 2023 Jul; 71():1-16. PubMed ID: 37172668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Copper homeostasis and cuproptosis in atherosclerosis: metabolism, mechanisms and potential therapeutic strategies.
    Yang S; Li Y; Zhou L; Wang X; Liu L; Wu M
    Cell Death Discov; 2024 Jan; 10(1):25. PubMed ID: 38218941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Copper Deposition in Polydopamine Nanostructure to Promote Cuproptosis by Catalytically Inhibiting Copper Exporters of Tumor Cells for Cancer Immunotherapy.
    Chang J; Yin W; Zhi H; Chen S; Sun J; Zhao Y; Huang L; Xue L; Zhang X; Zhang T; Dong H; Li Y
    Small; 2024 Feb; ():e2308565. PubMed ID: 38339770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cuproptosis status affects treatment options about immunotherapy and targeted therapy for patients with kidney renal clear cell carcinoma.
    Zhang G; Chen X; Fang J; Tai P; Chen A; Cao K
    Front Immunol; 2022; 13():954440. PubMed ID: 36059510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cuproptosis and cuproptosis-related genes: Emerging potential therapeutic targets in breast cancer.
    Liu X; Luo B; Wu X; Tang Z
    Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):189013. PubMed ID: 37918452
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elesclomol-copper synergizes with imidazole ketone erastin by promoting cuproptosis and ferroptosis in myelodysplastic syndromes.
    Gao Y; Jin F; Zhang P; Zheng C; Zheng X; Xie J; Lu Y; Tong X; Du J; Zhang J; Wang Y
    Biomed Pharmacother; 2024 Jun; 175():116727. PubMed ID: 38733771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cuproptosis-related gene index: A predictor for pancreatic cancer prognosis, immunotherapy efficacy, and chemosensitivity.
    Huang X; Zhou S; Tóth J; Hajdu A
    Front Immunol; 2022; 13():978865. PubMed ID: 36090999
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitochondrial-Targeted Copper Delivery for Cuproptosis-Based Synergistic Cancer Therapy.
    Deng J; Zhuang H; Shao S; Zeng X; Xue P; Bai T; Wang X; Shangguan S; Chen Y; Yan S; Huang W
    Adv Healthc Mater; 2024 Mar; ():e2304522. PubMed ID: 38530073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring cuproptosis as a mechanism and potential intervention target in cardiovascular diseases.
    Yang Y; Feng Q; Luan Y; Liu H; Jiao Y; Hao H; Yu B; Luan Y; Ren K
    Front Pharmacol; 2023; 14():1229297. PubMed ID: 37637426
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cuproptosis and its application in different cancers: an overview.
    Xu L; Liu K; Wang F; Su Y
    Mol Cell Biochem; 2023 Dec; 478(12):2683-2693. PubMed ID: 36914880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The mechanism of cuproptosis in Parkinson's disease.
    Huang M; Zhang Y; Liu X
    Ageing Res Rev; 2024 Mar; 95():102214. PubMed ID: 38311254
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The implications and prospect of cuproptosis-related genes and copper transporters in cancer progression.
    Zhao Q; Qi T
    Front Oncol; 2023; 13():1117164. PubMed ID: 36925927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Cross-Communication of Cuproptosis and Regulated Cell Death in Human Pathophysiology.
    Tsui KH; Hsiao JH; Lin LT; Tsang YL; Shao AN; Kuo CH; Chang R; Wen ZH; Li CJ
    Int J Biol Sci; 2024; 20(1):218-230. PubMed ID: 38164173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
    Song S; Zhang M; Xie P; Wang S; Wang Y
    Front Immunol; 2022; 13():978909. PubMed ID: 36341328
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of cuproptosis and Cu metabolism-associated genes to chronic obstructive pulmonary disease.
    Qi W; Liu L; Zeng Q; Zhou Z; Chen D; He B; Gong S; Gao L; Wang X; Xiong J; Cai D; Yu S; Zhao L
    J Cell Mol Med; 2023 Dec; 27(24):4034-4044. PubMed ID: 37801050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.